Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology
Authors:
- 1 September 2004
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (6) , 615-621
Abstract
Summary: Backgound : Patients being investigated for symptoms of abdominal pain, diarrhoea and or weight loss often undergo small bowel radiology as part of their diagnostic workup mainly to exclude inflammatory bowel disease.Aim : To assess and compare the utility of a single faecal calprotectin estimation to barium follow through as well as conventional inflammatory markers such as erythrocyte sedimentation rate and C‐reactive protein in exclusion of intestinal inflammation.Methods : Seventy‐three consecutive cases undergoing barium follow through for investigation of symptoms of diarrhoea and or abdominal pain with or without weight loss were studied. The control group comprised 25 cases with known active Crohn's disease (positive controls), 26 normal healthy volunteers (negative controls) and 25 cases of irritable bowel syndrome diagnosed by Rome II criteria. Symptoms, erythrocyte sedimentation rate and C‐reactive protein were recorded at recruitment and a single stool sample assayed for calprotectin within 7 days prior to or after barium follow through.Results : The median calprotectin value in the active Crohn's group, irritable bowel syndrome group and normal volunteers was 227 μg/g of stool, 19 and 10 μg/g respectively (P < 0.0001). A faecal calprotectin above a cut‐off value of 60 μg/g was able to predict all nine cases with an abnormal barium follow through as well as all six cases with a normal barium follow through but with organic intestinal disease. The negative predictive value of a single calprotectin result below 60 μg/g of stool was 100% compared with 91% each for erythrocyte sedimentation rate > 10 mm and C‐reactive protein > 6 mg/L and 84% for a combination of erythrocyte sedimentation rate and C‐reactive protein in predicting absence of organic intestinal disease.Conclusion : A single stool calprotectin value < 60 μg/g of stool obviates the need for further barium radiology of the small bowel, is more accurate than measurement of erythrocyte sedimentation rate or C‐reactive protein and effectively excludes Crohn's disease or non‐functional gastrointestinal disease.Keywords
This publication has 19 references indexed in Scilit:
- Faecal calprotectin: a new marker for Crohn's disease?Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2004
- Hyperzincaemia and hypercalprotectinaemia: a new disorder of zinc metabolismThe Lancet, 2002
- Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal diseaseGastroenterology, 2002
- A New Fecal Calprotectin Test for Colorectal Neoplasia: Clinical Results and Comparison with Previous MethodScandinavian Journal of Gastroenterology, 2001
- Fecal calprotectin as an index of intestinal inflammationDrugs of Today, 2001
- Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel diseaseGastroenterology, 2000
- Faecal calprotectin levels in a high risk population for colorectal neoplasiaGut, 2000
- High prevalence of NSAID enteropathy as shown by a simple faecal testGut, 1999
- Correlation between Faecal Excretion of Indium-111-Labelled Granulocytes and Calprotectin, a Granulocyte Marker Protein, in Patients with Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 1999
- Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker ProteinDigestion, 1997